RxDoctor Payments Data

Donna Loughlin Pherribo, DO

Family Medicine · Hammonton, NJNPI 1881650703

Payments from drug & device makers

$2,752in general payments, 2019–2025

Across 155 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$669
  • AstraZeneca$371
  • Lilly USA, LLC$332
  • Johnson & Johnson$266
  • Boehringer Ingelheim$174
  • Pfizer$140
  • plus $801 from 15 others

What the payments were for

  • Food & beverage$2,752100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,752 in reported general payments places this provider in the 80th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$38,517
Medicare patients
187
Services billed
513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PercocetOxycodone Hcl/Acetaminophen23$101,387
OzempicSemaglutide54$73,805
FarxigaDapagliflozin Propanediol37$44,941
EliquisApixaban33$32,217
JardianceEmpagliflozin19$30,250
JanuviaSitagliptin Phosphate14$20,385
XareltoRivaroxaban17$17,284
Tresiba Flextouch U-100Insulin Degludec16$13,087
Breo ElliptaFluticasone/Vilanterol11$7,919
CreonLipase/Protease/Amylase11$4,040
Rosuvastatin Calcium225$3,852
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,710
Atorvastatin Calcium233$2,874
Levothyroxine Sodium256$2,716
Losartan Potassium188$1,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$669$73,80554 claims
AstraZenecaFarxiga$371$44,94137 claims
PfizerEliquis$140$32,21733 claims
Boehringer IngelheimJardiance$174$30,25019 claims
MerckJanuvia$101$20,38514 claims
Johnson & JohnsonXarelto$266$17,28417 claims
GSKBreo Ellipta$33$7,91911 claims
AbbVieCreon, Synthroid$57$5,41139 claims
Almatica Pharma LLCSertraline Hcl$36$1,30092 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Hammonton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →